Serial haemostatic monitoring of dogs with multicentric lymphoma

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Lymphoma is the most common haematopoietic malignancy in dogs and it has been associated with hypercoagulability and subsequent thromboembolism. The objectives of this study were to serially characterize the haemostatic status of dogs with multicentric lymphoma. Thromboelastography, thrombin-antithrombin complex concentration and routine haematology and coagulation panels were measured. Twenty-seven dogs were included in the study and 15 completed the study in remission. At presentation, 81% (22/27) of dogs with multicentric lymphoma had altered haemostatic profiles consistent with hypercoagulability. Laboratory evidence of hypercoagulability did not resolve during treatment or for up to 1 month following attainment of clinical remission. Accelerated rate of clot formation at the time of chemotherapeutic protocol completion was associated with decreased survival time. We concluded that dogs with multicentric lymphoma were frequently hypercoagulable from presentation through 4weeks after the completion of chemotherapy. Increased angle and shortened K in dogs that have successfully completed their chemotherapeutic protocol may be associated with shorter survival times.

Original languageEnglish (US)
JournalVeterinary and Comparative Oncology
DOIs
StateAccepted/In press - 2013

Fingerprint

Hemostatics
lymphoma
Lymphoma
Dogs
Thrombophilia
monitoring
dogs
remission
Thrombelastography
thrombin
Thromboembolism
Hematology
Hematologic Neoplasms
hematology
coagulation
drug therapy
Drug Therapy

Keywords

  • Canine
  • Coagulation
  • Haemostasis
  • Lymphoma
  • Thromboelastography

ASJC Scopus subject areas

  • veterinary(all)

Cite this

@article{ae861899bdf54fc48d678fea2dda7024,
title = "Serial haemostatic monitoring of dogs with multicentric lymphoma",
abstract = "Lymphoma is the most common haematopoietic malignancy in dogs and it has been associated with hypercoagulability and subsequent thromboembolism. The objectives of this study were to serially characterize the haemostatic status of dogs with multicentric lymphoma. Thromboelastography, thrombin-antithrombin complex concentration and routine haematology and coagulation panels were measured. Twenty-seven dogs were included in the study and 15 completed the study in remission. At presentation, 81{\%} (22/27) of dogs with multicentric lymphoma had altered haemostatic profiles consistent with hypercoagulability. Laboratory evidence of hypercoagulability did not resolve during treatment or for up to 1 month following attainment of clinical remission. Accelerated rate of clot formation at the time of chemotherapeutic protocol completion was associated with decreased survival time. We concluded that dogs with multicentric lymphoma were frequently hypercoagulable from presentation through 4weeks after the completion of chemotherapy. Increased angle and shortened K in dogs that have successfully completed their chemotherapeutic protocol may be associated with shorter survival times.",
keywords = "Canine, Coagulation, Haemostasis, Lymphoma, Thromboelastography",
author = "Amir Kol and Marks, {Stanley L} and Skorupski, {Katherine A} and Kass, {Philip H} and T. Guerrero and Gosselin, {R. C.} and Borjesson, {Dori L}",
year = "2013",
doi = "10.1111/vco.12041",
language = "English (US)",
journal = "Veterinary and Comparative Oncology",
issn = "1476-5829",
publisher = "Wiley-Blackwell",

}

TY - JOUR

T1 - Serial haemostatic monitoring of dogs with multicentric lymphoma

AU - Kol, Amir

AU - Marks, Stanley L

AU - Skorupski, Katherine A

AU - Kass, Philip H

AU - Guerrero, T.

AU - Gosselin, R. C.

AU - Borjesson, Dori L

PY - 2013

Y1 - 2013

N2 - Lymphoma is the most common haematopoietic malignancy in dogs and it has been associated with hypercoagulability and subsequent thromboembolism. The objectives of this study were to serially characterize the haemostatic status of dogs with multicentric lymphoma. Thromboelastography, thrombin-antithrombin complex concentration and routine haematology and coagulation panels were measured. Twenty-seven dogs were included in the study and 15 completed the study in remission. At presentation, 81% (22/27) of dogs with multicentric lymphoma had altered haemostatic profiles consistent with hypercoagulability. Laboratory evidence of hypercoagulability did not resolve during treatment or for up to 1 month following attainment of clinical remission. Accelerated rate of clot formation at the time of chemotherapeutic protocol completion was associated with decreased survival time. We concluded that dogs with multicentric lymphoma were frequently hypercoagulable from presentation through 4weeks after the completion of chemotherapy. Increased angle and shortened K in dogs that have successfully completed their chemotherapeutic protocol may be associated with shorter survival times.

AB - Lymphoma is the most common haematopoietic malignancy in dogs and it has been associated with hypercoagulability and subsequent thromboembolism. The objectives of this study were to serially characterize the haemostatic status of dogs with multicentric lymphoma. Thromboelastography, thrombin-antithrombin complex concentration and routine haematology and coagulation panels were measured. Twenty-seven dogs were included in the study and 15 completed the study in remission. At presentation, 81% (22/27) of dogs with multicentric lymphoma had altered haemostatic profiles consistent with hypercoagulability. Laboratory evidence of hypercoagulability did not resolve during treatment or for up to 1 month following attainment of clinical remission. Accelerated rate of clot formation at the time of chemotherapeutic protocol completion was associated with decreased survival time. We concluded that dogs with multicentric lymphoma were frequently hypercoagulable from presentation through 4weeks after the completion of chemotherapy. Increased angle and shortened K in dogs that have successfully completed their chemotherapeutic protocol may be associated with shorter survival times.

KW - Canine

KW - Coagulation

KW - Haemostasis

KW - Lymphoma

KW - Thromboelastography

UR - http://www.scopus.com/inward/record.url?scp=84878117351&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878117351&partnerID=8YFLogxK

U2 - 10.1111/vco.12041

DO - 10.1111/vco.12041

M3 - Article

C2 - 23710569

AN - SCOPUS:84939651860

JO - Veterinary and Comparative Oncology

JF - Veterinary and Comparative Oncology

SN - 1476-5829

ER -